ERBB2 and cancer: Taken together, the CD19-CAR T cells can be efficiently redirected by the CD19-4D5scFv protein against the ErbB2high cancer cells in vitro and in vivo, without attacking the human fibroblasts with the physiological ErbB2 levels.